{"id":"docetaxel-cisplatin-5-fu-and-cetuximab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Rash"},{"rate":"5-20%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel works by stabilizing microtubules, preventing cell division, and ultimately leading to cell death. Cisplatin forms crosslinks in DNA, causing DNA damage and triggering cell death. 5-FU inhibits thymidylate synthase, an enzyme necessary for DNA synthesis, thereby preventing cancer cell growth. Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling pathways that promote cell proliferation.","oneSentence":"Docetaxel inhibits microtubule dynamics, Cisplatin induces DNA crosslinks, 5-FU inhibits thymidylate synthase, and Cetuximab binds to the epidermal growth factor receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:54.418Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic breast cancer, Colorectal cancer, Head and neck cancer"},{"name":"Metastatic nasopharyngeal carcinoma"}]},"trialDetails":[{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT06943820","phase":"PHASE1, PHASE2","title":"AK129 Combination Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-21","conditions":"Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma","enrollment":230},{"nctId":"NCT06714266","phase":"PHASE2","title":"Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-12-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":30},{"nctId":"NCT00868491","phase":"PHASE2","title":"Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2008-03","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT00502463","phase":"NA","title":"Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial","status":"COMPLETED","sponsor":"Austrian South Oncology Group","startDate":"2007-10-03","conditions":"Head and Neck Cancer","enrollment":51},{"nctId":"NCT02268695","phase":"PHASE2","title":"Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2014-10-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":541},{"nctId":"NCT01884259","phase":"PHASE2","title":"Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2013-05","conditions":"Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III","enrollment":100},{"nctId":"NCT04508829","phase":"PHASE2","title":"Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Oropharyngeal Carcinoma","enrollment":52},{"nctId":"NCT00721513","phase":"PHASE2","title":"Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-09","conditions":"Head and Neck Cancer","enrollment":20},{"nctId":"NCT00716391","phase":"PHASE3","title":"TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.","status":"COMPLETED","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","startDate":"2008-07-07","conditions":"Head and Neck Cancer","enrollment":519},{"nctId":"NCT00765011","phase":"PHASE2","title":"TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer","status":"COMPLETED","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":94},{"nctId":"NCT01181401","phase":"PHASE2","title":"InductionChemo-Radio-Antibody-Treatment","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2010-08","conditions":"Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck","enrollment":94},{"nctId":"NCT01233843","phase":"PHASE3","title":"Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2009-05-18","conditions":"Squamous Cell Head and Neck Carcinoma","enrollment":370},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT01221753","phase":"PHASE2","title":"Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-07","conditions":"Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus","enrollment":7},{"nctId":"NCT00999700","phase":"PHASE3","title":"Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2009-09","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":282},{"nctId":"NCT01326559","phase":"PHASE2","title":"Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)","status":"COMPLETED","sponsor":"Hong Kong Nasopharyngeal Cancer Study Group Limited","startDate":"2010-06","conditions":"Nasopharyngeal Carcinoma","enrollment":33},{"nctId":"NCT01467115","phase":"PHASE2","title":"Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2010-03","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT00599131","phase":"PHASE2","title":"Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-08","conditions":"Cancer of Larynx","enrollment":4},{"nctId":"NCT00508664","phase":"PHASE2","title":"Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)","status":"COMPLETED","sponsor":"ClinAssess","startDate":"2007-07","conditions":"Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma","enrollment":180},{"nctId":"NCT00735345","phase":"PHASE2","title":"Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma","status":"TERMINATED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2008-08","conditions":"Esophageal Cancer","enrollment":50},{"nctId":"NCT01086826","phase":"PHASE3","title":"Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Associazione Volontari Pazienti Oncologici","startDate":"2008-03","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":320},{"nctId":"NCT00733889","phase":"PHASE2","title":"A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2006-12","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT00941135","phase":"PHASE2","title":"Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab","status":"TERMINATED","sponsor":"Fundacion Miguel Servet","startDate":"2009-05","conditions":"Laryngeal Neoplasms","enrollment":70},{"nctId":"NCT00169247","phase":"PHASE2","title":"Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2005-10","conditions":"Larynx Cancer, Hypopharynx Cancer","enrollment":156},{"nctId":"NCT00402545","phase":"PHASE1","title":"C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-01","conditions":"Head and Neck Neoplasms","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Docetaxel, Cisplatin, 5-FU and Cetuximab","genericName":"Docetaxel, Cisplatin, 5-FU and Cetuximab","companyName":"Hong Kong Nasopharyngeal Cancer Study Group Limited","companyId":"hong-kong-nasopharyngeal-cancer-study-group-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel inhibits microtubule dynamics, Cisplatin induces DNA crosslinks, 5-FU inhibits thymidylate synthase, and Cetuximab binds to the epidermal growth factor receptor. Used for Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic breast cancer, Colorectal cancer, Head and neck cancer, Metastatic nasopharyngeal carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}